trial summary · NCT07466498
Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial
Estrogen for Quality-of-Life and Immune Modulation in Prostate Cancer (EQUIP)
Trial record from the TrialBase DB dataset, status RECRUITING, condition Castration-Sensitive Prostate Adenocarcinoma, sponsored by Fred Hutchinson Cancer Center. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
This phase II trial compares giving estrogen with an androgen receptor signaling inhibitor to standard of care luteinizing hormone-releasing hormone (LHRH) analogues with an androgen receptor signaling inhibitor for improving quality of life for patients with hormone sensitive prostate cancer that is newly diagnosed or that has come back after a period of improvement (recurrent) and has spread from where it first started (primary site) to other places in the body (metastatic). Standard prostate cancer treatment decreases hormone levels, specifically estrogen, in the body which can lead to hot flashes, fatigue, decreased bone health, and cardiovascular and metabolic dysfunction. Transdermal estrogen may help to alleviate these symptoms. Androgen receptor signaling inhibitors work by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of tumor cells. LHRH analogues are a type of androgen deprivation therapy that blocks the use of androgen by the tumor cells. Giving estrogen with androgen receptor signaling inhibitor may improve quality of life in men with newly diagnosed or recurrent metastatic hormone sensitive prostate cancer.
Source record: https://clinicaltrials.gov/study/NCT07466498
Facts
| registry id | NCT07466498 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE2 |
| study type | INTERVENTIONAL |
| lead condition | Castration-Sensitive Prostate Adenocarcinoma |
| sponsor | Fred Hutchinson Cancer Center |
| sponsor class | OTHER |
| enrollment | 60 |
| start date | 2026-11-01 |
| primary completion | 2029-06-01 |
| completion | 2029-06-01 |
| results posted | not reported |
Conditions
- Castration-Sensitive Prostate Adenocarcinoma
- Metastatic Castration-Sensitive Prostate Adenocarcinoma
- Stage IVB Prostate Cancer AJCC v8
Interventions
- Androgen Receptor Pathway Inhibitor
- Transdermal Estrogen
- Bone Scan
- Computed Tomography
- Dual X-ray Absorptiometry
- Gonadotropin-releasing Hormone Analog
- Magnetic Resonance Imaging
- Survey Administration
- Biospecimen Collection
Countries
- United States
Intervention types: BIOLOGICAL, DRUG, OTHER, PROCEDURE
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.